Publications by authors named "K Mizoi"

The Ussing chamber is a tool for analyzing drug absorption. We investigated whether the Ussing chamber can be used to analyze the process from digestion to absorption of protein in the gastrointestinal tract. Mixtures containing infant formula, whole cow's milk, processed soy milk, enteral nutrition, or human breast milk, were placed in the apical membrane side equipped with Caco-2 cells.

View Article and Find Full Text PDF

Breast cancer resistance protein (BCRP) is a drug efflux transporter expressed on the epithelial cells of the small intestine and on the lateral membrane of the bile duct in the liver; and is involved in the efflux of substrate drugs into the gastrointestinal lumen and secretion into bile. Recently, the area under the plasma concentration-time curve (AUC) of rosuvastatin (ROS), a BCRP substrate drug, has been reported to be increased by BCRP inhibitors, and BCRP-mediated drug-drug interaction (DDI) has attracted attention. In this study, we performed a ROS uptake study using human colon cancer-derived Caco-2 cells and confirmed that BCRP inhibitors significantly increased the intracellular accumulation of ROS.

View Article and Find Full Text PDF

Lung cancer metastasis often leads to a poor prognosis for patients. Mesenchymal-epithelial transition (MET) is one key process associated with metastasis. MET has also been linked to multidrug drug resistance (MDR).

View Article and Find Full Text PDF

It has recently been reported that cholangiocyte organoids can be established from primary human hepatocytes. The purpose of this study was to culture the organoids in monolayers on inserts to investigate the biliary excretory capacity of drugs. Cholangiocyte organoids prepared from hepatocytes had significantly higher mRNA expression of CK19, a bile duct epithelial marker, compared to hepatocytes.

View Article and Find Full Text PDF
Article Synopsis
  • - This report investigates how certain drugs interact with P-glycoprotein (P-gp), which may influence the movement of hormones like testosterone and androstenedione across the blood-brain barrier (BBB).
  • - The study found that several drugs can disrupt P-gp's action, leading to higher levels of testosterone and androstenedione inside cells by inhibiting their removal.
  • - In rat models, the research demonstrated that the BBB restricts these hormones' entry into the brain but that certain drugs can enhance their permeability by targeting P-gp.
View Article and Find Full Text PDF